vs
BillionToOne, Inc.（BLLN）与GRAIL, Inc.（GRAL）财务数据对比。点击上方公司名可切换其他公司
BillionToOne, Inc.的季度营收约是GRAIL, Inc.的1.9倍（$83.5M vs $43.6M）。BillionToOne, Inc.净利率更高（6.8% vs -227.5%，领先234.3%）。BillionToOne, Inc.同比增速更快（117.4% vs 14.0%）。BillionToOne, Inc.自由现金流更多（$6.5M vs $-63.9M）
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
GRAIL是2015年成立的美国生物技术企业，总部位于加利福尼亚州门洛帕克，核心业务是研发面向无症状人群的癌症早期筛查检测产品。该公司最初是基因测序企业Illumina旗下的初创子公司，2021年被Illumina全资收购。
BLLN vs GRAL — 直观对比
营收规模更大
BLLN
是对方的1.9倍
$43.6M
营收增速更快
BLLN
高出103.4%
14.0%
净利率更高
BLLN
高出234.3%
-227.5%
自由现金流更多
BLLN
多$70.3M
$-63.9M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $83.5M | $43.6M |
| 净利润 | $5.7M | $-99.2M |
| 毛利率 | 69.9% | — |
| 营业利润率 | 11.5% | -285.4% |
| 净利率 | 6.8% | -227.5% |
| 营收同比 | 117.4% | 14.0% |
| 净利润同比 | 138.3% | -2.2% |
| 每股收益（稀释后） | $0.10 | $-2.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLLNGRAL
| Q4 25 | — | $43.6M | ||
| Q3 25 | $83.5M | $36.2M | ||
| Q2 25 | — | $35.5M | ||
| Q1 25 | — | $31.8M | ||
| Q4 24 | — | $38.3M | ||
| Q3 24 | $38.4M | $28.7M | ||
| Q2 24 | — | $32.0M | ||
| Q1 24 | — | $26.7M |
净利润BLLNGRAL
| Q4 25 | — | $-99.2M | ||
| Q3 25 | $5.7M | $-89.0M | ||
| Q2 25 | — | $-114.0M | ||
| Q1 25 | — | $-106.2M | ||
| Q4 24 | — | $-97.1M | ||
| Q3 24 | $-14.9M | $-125.7M | ||
| Q2 24 | — | $-1.6B | ||
| Q1 24 | — | $-218.9M |
毛利率BLLNGRAL
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率BLLNGRAL
| Q4 25 | — | -285.4% | ||
| Q3 25 | 11.5% | -346.2% | ||
| Q2 25 | — | -446.9% | ||
| Q1 25 | — | -482.5% | ||
| Q4 24 | — | -358.0% | ||
| Q3 24 | -32.9% | -640.5% | ||
| Q2 24 | — | -5133.8% | ||
| Q1 24 | — | -851.1% |
净利率BLLNGRAL
| Q4 25 | — | -227.5% | ||
| Q3 25 | 6.8% | -245.8% | ||
| Q2 25 | — | -320.7% | ||
| Q1 25 | — | -333.6% | ||
| Q4 24 | — | -253.8% | ||
| Q3 24 | -38.8% | -438.7% | ||
| Q2 24 | — | -4958.8% | ||
| Q1 24 | — | -819.3% |
每股收益（稀释后）BLLNGRAL
| Q4 25 | — | $-2.37 | ||
| Q3 25 | $0.10 | $-2.46 | ||
| Q2 25 | — | $-3.18 | ||
| Q1 25 | — | $-3.10 | ||
| Q4 24 | — | $-1.49 | ||
| Q3 24 | $-1.47 | $-3.94 | ||
| Q2 24 | — | $-51.06 | ||
| Q1 24 | — | $-7.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.2M | $249.7M |
| 总债务越低越好 | $55.0M | — |
| 股东权益账面价值 | $-239.5M | $2.6B |
| 总资产 | $327.5M | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BLLNGRAL
| Q4 25 | — | $249.7M | ||
| Q3 25 | $195.2M | $126.9M | ||
| Q2 25 | — | $127.4M | ||
| Q1 25 | — | $133.9M | ||
| Q4 24 | — | $214.2M | ||
| Q3 24 | — | $853.6M | ||
| Q2 24 | — | $958.8M | ||
| Q1 24 | — | $199.7M |
总债务BLLNGRAL
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BLLNGRAL
| Q4 25 | — | $2.6B | ||
| Q3 25 | $-239.5M | $2.2B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.4B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | $-242.9M | $2.6B | ||
| Q2 24 | — | $2.7B | ||
| Q1 24 | — | — |
总资产BLLNGRAL
| Q4 25 | — | $2.9B | ||
| Q3 25 | $327.5M | $2.6B | ||
| Q2 25 | — | $2.7B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | $3.1B | ||
| Q2 24 | — | $3.3B | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.8M | $-63.8M |
| 自由现金流经营现金流 - 资本支出 | $6.5M | $-63.9M |
| 自由现金流率自由现金流/营收 | 7.7% | -146.5% |
| 资本支出强度资本支出/营收 | 8.8% | 0.2% |
| 现金转化率经营现金流/净利润 | 2.42× | — |
| 过去12个月自由现金流最近4个季度 | — | $-299.9M |
8季度趋势，按日历期对齐
经营现金流BLLNGRAL
| Q4 25 | — | $-63.8M | ||
| Q3 25 | $13.8M | $-63.2M | ||
| Q2 25 | — | $-77.0M | ||
| Q1 25 | — | $-95.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-104.6M | ||
| Q2 24 | — | $-171.8M | ||
| Q1 24 | — | $-207.3M |
自由现金流BLLNGRAL
| Q4 25 | — | $-63.9M | ||
| Q3 25 | $6.5M | $-63.6M | ||
| Q2 25 | — | $-77.3M | ||
| Q1 25 | — | $-95.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-105.6M | ||
| Q2 24 | — | $-173.2M | ||
| Q1 24 | — | $-209.8M |
自由现金流率BLLNGRAL
| Q4 25 | — | -146.5% | ||
| Q3 25 | 7.7% | -175.8% | ||
| Q2 25 | — | -217.6% | ||
| Q1 25 | — | -298.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -368.4% | ||
| Q2 24 | — | -541.7% | ||
| Q1 24 | — | -785.3% |
资本支出强度BLLNGRAL
| Q4 25 | — | 0.2% | ||
| Q3 25 | 8.8% | 1.1% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | 9.5% |
现金转化率BLLNGRAL
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
GRAL
| Screening Revenue | $42.3M | 97% |
| Developmental Services Revenue | $1.3M | 3% |
